Skip to main content

Table 1 Clinical features and prognosis for the AIT-free patients and those receiving AIT

From: Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study

 

Missing data

AIT-free patients n = 275

Patients receiving AIT during their ICU stay n = 585

p value

Male, n (%)

1/4

166 (61)

386 (66)

NS

Age, years, median [IQR]

3/4

55 [40–71]

59 [48–72]

< 0.01

Underlying diseases

 Diabetes, n (%)

0

45 (16)

91 (16)

NS

 Cardiovascular disease, n (%)

0

157 (57)

342 (58)

NS

 Respiratory disease, n (%)

0

44 (16)

100 (17)

NS

 Renal disease, n (%)

0

24 (9)

31 (5)

NS

 Liver disease, n (%)

0/1

30 (11)

63 (11)

NS

 Smoking, n (%)

0

137 (50)

251 (43)

NS

 Alcoholism, n (%)

0/1

128 (47)

247 (42)

NS

Attributable cause of pancreatitis

 Alcoholism, n (%)

0

80 (29)

146 (25)

NS

 Gallstones, n (%)

0

97 (35)

247 (42)

NS

 Post-ERCP, n (%)

0

9 (3)

47 (8)

< 0.01

 Hypertriglyceridaemia, n (%)

0

26 (9)

31 (5)

< 0.05

 Cancer, n (%)

0

8 (3)

6 (1)

NS

 Toxic, n (%)

0

4 (1)

17 (3)

NS

 Undetermined, n (%)

0

51 (19)

96 (16)

NS

Clinical presentation on admission

 Pain onset/ICU admission interval, days, median [IQR]

0

2 [1–3]

3 [1–8]

< 0.001

 Oliguria/anuria, n (%)

0

120 (44)

253 (43)

NS

 BISAP score, median [IQR]

12/22

1 [0–1]

1 [1–2]

< 0.001

 Balthazar score E, n (%)

0

137 (50)

356 (61)

< 0.01

Severity criteria on admission

 SOFA score, median [IQR]

9/14

3 [1–5]

5 [3–7]

< 0.001

 Respiratory failure*, n (%)

0

39 (14)

207 (35)

< 0.001

 Cardiovascular failure*, n (%)

0

37 (13)

202 (35)

< 0.001

 Renal failure*, n (%)

0

43 (16)

100 (17)

NS

 Septic shock, n (%)

0

3 (1)

114 (19)

< 0.001

 Acute respiratory distress syndrome, n (%)

0

9 (3)

53 (9)

< 0.01

Therapeutic management on admission

 Vasoactive support, n (%)

0/1

38 (14)

207 (35)

< 0.001

 Mechanical ventilation, n (%)

1/5

38 (14)

187 (32)

< 0.001

 Fluid loading, n (%)

2/12

178 (65)

447 (78)

< 0.001

 Renal replacement therapy, n (%)

1/10

16 (6)

62 (11)

< 0.05

Main treatments between day > 0 and day 30

 Need for red blood cell transfusion, n (%)

0

31 (11)

195 (33)

< 0.001

 Number of days of mechanical ventilation

1/2

0 [0–0]

4 [0–16]

< 0.001

 Vasoactive support, n (%)

0/1

59 (21)

335 (57)

< 0.001

 Renal replacement therapy, n (%)

1/1

42 (15)

178 (30)

< 0.001

 Duration of RRT, days, median [IQR]

14/0

2 [2–4]

7 [2–15]

< 0.001

Main complications between day > 0 and day 30

 Acute respiratory distress syndrome, n (%)

0/2

40 (15)

201 (34)

< 0.001

 Septic shock, n (%)

24/47

4 (2)

210 (39)

< 0.001

 Pancreatic necrosis, n (%)

12/18

164 (62)

393 (69)

< 0.05

 Infected necrosis, n (%)

15/29

5 (2)

200 (36)

< 0.001

 Gastro-intestinal perforation, n (%)

12/32

4 (1)

50 (9)

< 0.001

 Vascular thrombosis, n (%)

12/26

22 (8)

86 (15)

< 0.01

 Acute mesenteric ischaemia, n (%)

12/28

25 (10)

63 (11)

NS

 Intra-abdominal collection, n (%)

10/22

37 (14)

242 (43)

< 0.001

 Abdominal compartment syndrome, n (%)

12/26

17 (6)

66 (12)

< 0.05

 Haemorrhage, n (%)

11/26

19 (7)

81 (14)

< 0.01

 Peritonitis, n (%)

12/30

3 (1)

85 (15)

< 0.001

 Cholangitis, n (%)

15/25

2 (1)

57 (10)

< 0.001

 Digestive fistula, n (%)

12/28

1 (1)

30 (5)

< 0.001

Clinical management between day > 0 and day 30

 Endoscopic necrosectomy, n (%)

2/6

24 (9)

152 (26)

< 0.001

 Surgical necrosectomy, n (%)

0/6

32 (12)

219 (38)

< 0.001

 Radiological drainage, n (%)

0/6

8 (3)

120 (21)

< 0.001

Duration of ICU stay, days, median [IQR]

0

3 [1–6]

12 [4–27]

< 0.001

ICU readmission, n (%)

0/1

6 (2)

50 (9)

< 0.001

Hospital mortality rate, n (%)

0

54 (20)

143 (24)

NS

Time to death, days, median [IQR]

0

1.5 [1–2]

12 [2–34]

< 0.001

  1. NS non-significant, NA not applicable, ERCP endoscopic retrograde cholangiopancreatography
  2. *According to the definition of the SOFA score